BioIntelliSense announced that it won FDA 510(k) clearance for its BioSticker on-body sensor for scalable remote care and initiated the U.S. commercial launch of the product last week.
The BioSticker is designed to allow for continuous monitoring of vital signs and actionable insights to provide opportunities for early detection of potentially avoidable complications from a home setting. The company’s medical-grade data-as-a-service platform contributes the data and analytics to the BioSticker to potentially create an accurate, cost-effective solution.